NorthlineHealth
Join
← FormularyTracking · Category 2

Neuropeptide · Delta Sleep-Inducing Peptide

DSIP

Sleep / delta-wave

Status
On watchlist — not yet prescribable
Get notified on reclassification

Mechanism

DSIP (delta sleep-inducing peptide) is a nonapeptide first isolated from rabbit cerebral venous blood during slow-wave sleep. It promotes delta EEG activity, modulates LH and GH secretion, and has demonstrated antioxidant and stress-protective properties. Mechanism of action remains under investigation.

Indications

→Sleep quality and delta-wave promotion
→Insomnia and circadian disruption
→Stress-related hormonal dysregulation
→Pain modulation (research)

Regulatory status

DSIP has no FDA approval and is a Category 2 substance under 503A, prohibiting compounding. Research use only in the US. Northline monitors regulatory status.

References

01Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986.
02FDA 503A Category 2 — ineligible for compounding.

This fact sheet is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed clinician based on individual medical necessity. Not all patients qualify.